KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBITDA (2016 - 2025)

Travere Therapeutics' EBITDA history spans 15 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, EBITDA rose 104.37% year-over-year to $2.6 million; the TTM value through Dec 2025 reached -$26.7 million, up 91.67%, while the annual FY2025 figure was -$26.7 million, 91.67% up from the prior year.
  • EBITDA reached $2.6 million in Q4 2025 per TVTX's latest filing, down from $25.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $150.9 million in Q3 2023 to a low of -$136.5 million in Q1 2024.
  • Average EBITDA over 5 years is -$45.9 million, with a median of -$56.8 million recorded in 2024.
  • Peak YoY movement for EBITDA: crashed 3653.67% in 2021, then soared 321.09% in 2023.
  • A 5-year view of EBITDA shows it stood at -$51.6 million in 2021, then plummeted by 33.76% to -$69.0 million in 2022, then decreased by 27.44% to -$88.0 million in 2023, then surged by 32.56% to -$59.3 million in 2024, then soared by 104.37% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's EBITDA are $2.6 million (Q4 2025), $25.5 million (Q3 2025), and -$12.7 million (Q2 2025).